Stephanie Faubion, MD, and Fiona Baker, PhD, discuss how elinzanetant can play a role in sleep disturbances because of VMS, emerging data on the subject, and how to determine the right candidate for the NK1-3 dual-receptor antagonist.
Stephanie S. Faubion, MD, MBA, FACP, MSCP, IF
Advertisement
Faubion is director, Mayo Clinic Center for Women’s Health; professor and chair, Department of Medicine, Mayo Clinic, Jacksonville, Florida; and medical director, The Menopause Society.
Articles by Stephanie S. Faubion, MD, MBA, FACP, MSCP, IF
Shared decision-making around nonhormonal VMS and sleep management requires moving through contraindications, patient preferences, and monitoring burdens together, with elinzanetant's (Lynkuet) dual receptor profile making it a particularly relevant option for women with both VMS and sleep disruption—and with follow-up at 2 to 3 months essential to evaluating response, according to Stephanie S. Faubion, MD, MBA, FACP, MSCP, IF.
Two neurokinin receptor antagonists are now available for vasomotor symptom (VMS)-related sleep disruption, with elinzanetant's (Lynkuet) NK1 and NK3 dual-receptor profile potentially offering more targeted sleep benefit than fezolinetant's (Veozah) NK3-selective mechanism—but effective management requires systematic screening for obstructive sleep apnea, restless leg syndrome, and primary insomnia before attributing sleep disruption to VMS alone
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
FDA approves norelgestromin and ethinyl estradiol transdermal patch for contraception
2
Natural Cycles receives FDA clearance for AI-powered fertility algorithm
3
Bacterial vaginosis independently associated with increased STI co-infection
4
Joy Baker, MD, talks zuranolone's onset for postpartum depression
5